成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 2629-72-3 Chemical Structure| 2629-72-3

Structure of 2629-72-3

Chemical Structure| 2629-72-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 2629-72-3

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 2629-72-3 ]

CAS No. :2629-72-3
Formula : C8H11NO
M.W : 137.18
SMILES Code : OCCCC1=CC=NC=C1
MDL No. :MFCD00047457
InChI Key :PZVZGDBCMQBRMA-UHFFFAOYSA-N
Pubchem ID :72923

Safety of [ 2629-72-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 2629-72-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.38
Num. rotatable bonds 3
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 39.98
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

33.12 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.55
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.58
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.01
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.55
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.83
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.1

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.3
Solubility 6.85 mg/ml ; 0.0499 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.85
Solubility 19.4 mg/ml ; 0.142 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.63
Solubility 0.319 mg/ml ; 0.00232 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

 High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

 Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

 No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

 No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

 No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

 No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

 No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

 No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.72 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

 0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

 None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

 0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

 0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

 1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

 No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

 1.02

Application In Synthesis of [ 2629-72-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2629-72-3 ]

[ 2629-72-3 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 2629-72-3 ]
  • [ 7037-49-2 ]
YieldReaction ConditionsOperation in experiment
98% With hydrogenchloride; Adam?s catalyst; hydrogen; In methanol; water; under 60.006 Torr; for 46h;Inert atmosphere; Under an atmosphere of argon platinum(IV)oxide (1.45 g, 6.4 mmol) was added to a solution of 16 (10.0 g, 72.89 mmol) in MeOH (110 mL) and 32percent hydrochloric acid (18 mL). The mixture was vigorously stirred under a low pressure of hydrogen (8 kPa) for 46 h. The major part of the catalyst was removed by filtration and the volatiles were removed under reduced pressure. The oily residue was taken up in 15percent aq NaOH (80 mL) and the product was extracted with CH2Cl2 (150 and 3 * 100 mL). The pooled extracts were washed with water (20 mL) and dried over Na2SO4. Evaporation of the volatiles and drying in vacuo yielded product 17 as a white crystalline, compact solid (10.3 g, 98percent) mp 58-60 °C. Rf = 0.2 (CH2Cl2/MeOH/28percent aq NH3 50:10:1). IR (Nujol) 3290, 1320 cm-1. 1H NMR (300 MHz, CD3OD) delta (ppm) 1.08-1.23 (m, 2H), 1.27-1.36 (m, 2H), 1.36-1.49 (m, 1H), 1.53-1.63 (m, 2H), 1.74 (br d, 2H, J ca 13.4 Hz), 2.59 (dt, 2H, J 12.4 2.6 Hz), 3.04 (td, 2H, J 12.4 2.9 Hz), 3.56 (t, 2H, J 6.6 Hz). 13C NMR (75 MHz, CD3OD) delta (ppm) 31.5, 34.8, 35.2, 38.0, 47.9, 64.0. MS (ESI, MeOH) m/z (percent) 287 (36) [2M+H]+, 144 (100) [M+H]+. C8H17NO (143.2).
palladium-carbon; In acetic acid; a 3-(4-piperidinyl)propanol 3-(4-piperidinyl)propanol was prepared by hydrogenation of 3-(4-pyridyl)propanol in acetic acid in the presence of Pd/C according to the method described in J. Org. Chem., 1962, 27, 2966-2967.
With hydrogen;5% rhodium-on-charcoal; In water; at 50℃; under 15514.9 Torr; Example 3 1-Methyl-4-Piperidinepropanol An Argonaut reaction vessel was charged with 4-pyridinepropanol (500.0 mg, 3.49 mmol) and 5percent Rh/C (62percent wet, 300.0 mg) in water (4.00 g). The resultant slurry was stirred at 500 RPM and the unit was pressurized with 300 psi of hydrogen. The resultant mixture was heated at 50° C. for about 4-4.5 h, during which time the hydrogen uptake ceased. The resultant mixture was then cooled to room temperature and a 37percent formaldehyde solution (340.0 mg, 4.19 mmol) was added in a single portion. The Argonaut vessel was sealed and the resultant slurry was stirred at 500 RPM, the unit was repressurized with 300 psi of hydrogen, and heated to 50° C. Hydrogen uptake ceased in about 1.2-1.5 h to yield the title compound, which was used in the next step without further purification or isolation. HPLC-MS analysis of an aliquot showed only C9H19NO MS: (Cl): m/z 158 (M++1)
With platinum(IV) oxide; hydrogen; In acetic acid; at 40℃; under 38011.4 Torr; for 24h; To a solution of 3- (pyridin-4-yl) propan-1-ol (20.0 g, 0.15 mol) in AcOH (300 mL) was added PtO2 (2.5 g, 11.0 mmol) . The mixture was sealed and stirred at 40 under 735 psi hydrogen for 24h. After cooling to rt, the catalyst was filtered off and the filtrate was concentrated under reduced pressure. The crude was dissolved with DCM (1L) and organic phase was washed with sat. Na2CO3 (100 mL × 3) , dried over anhydrous Na2SO4, filtered and concentrated to afford 3- (piperidin-4-yl) propan-1-ol which was used in next step without purification. LRMS m/z (M+H) 144.1 found, 144.1 required.

  • 2
  • [ 2629-72-3 ]
  • [ 142355-83-7 ]
  • 3
  • [ 2629-72-3 ]
  • [ 150349-65-8 ]
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 2629-72-3 ]

Alcohols

Chemical Structure| 5264-15-3

A209421 [5264-15-3]

4-(Pyridin-4-yl)butan-1-ol

Similarity: 1.00

Chemical Structure| 5344-27-4

A292233 [5344-27-4]

4-(2-Hydroxyethyl)pyridine

Similarity: 0.95

Chemical Structure| 60753-14-2

A176155 [60753-14-2]

4-(Pyridin-3-yl)butan-1-ol

Similarity: 0.87

Chemical Structure| 5223-06-3

A158492 [5223-06-3]

2-(5-Ethylpyridin-2-yl)ethanol

Similarity: 0.81

Chemical Structure| 6293-56-7

A260399 [6293-56-7]

2-(Pyridin-3-yl)ethanol

Similarity: 0.80

Related Parent Nucleus of
[ 2629-72-3 ]

Pyridines

Chemical Structure| 5264-15-3

A209421 [5264-15-3]

4-(Pyridin-4-yl)butan-1-ol

Similarity: 1.00

Chemical Structure| 5344-27-4

A292233 [5344-27-4]

4-(2-Hydroxyethyl)pyridine

Similarity: 0.95

Chemical Structure| 27876-24-0

A191188 [27876-24-0]

4-Hexylpyridine

Similarity: 0.89

Chemical Structure| 5335-75-1

A310726 [5335-75-1]

4-Butylpyridine

Similarity: 0.89

Chemical Structure| 4916-57-8

A697029 [4916-57-8]

1,2-Di(pyridin-4-yl)ethane

Similarity: 0.89